| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director | C/O ALUMIS INC., 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO | /s/ Srinivas Akkaraju | 09 Dec 2025 | 0001253170 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ALMS | Common Stock | Purchase | $581,473 | +64,969 | +6% | $8.95 | 1,143,845 | 05 Dec 2025 | By Samsara Opportunity Fund, L.P. | F1, F2 |
| transaction | ALMS | Common Stock | Purchase | $700,980 | +70,028 | +6.1% | $10.01 | 1,213,873 | 05 Dec 2025 | By Samsara Opportunity Fund, L.P. | F2, F3 |
| transaction | ALMS | Common Stock | Purchase | $551,307 | +51,380 | +4.2% | $10.73 | 1,265,253 | 05 Dec 2025 | By Samsara Opportunity Fund, L.P. | F2, F4 |
| holding | ALMS | Common Stock | 4,491,731 | 05 Dec 2025 | By Samsara BioCapital, L.P. | F5 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.48 to $9.4793 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| F2 | Shares are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.48 to $10.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.48 to $11.005 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
| F5 | Shares are directly held by Samsara BioCapital LP. ("Samsara LP"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |